Document is current
Any future updates will be listed below
-
Authors
Etienne, Samuel
Albrich, Werner C.
Pletz, Mathias W.
Panning, Marcus
Suarez Domenech, Vivian
Eberhardt, Frank
Barten-Neiner, Grit
Stolz, Daiana
,
-
Funding
Funding for this research was provided by:
Pfizer Switzerland AG
University of Basel
- License Information
-
More Information
Article History
Received: 26 September 2025
Accepted: 19 November 2025
First Online: 27 November 2025
Declarations
:
: Werner C. Albrich: Honoraria: Pfizer, GSK, MSD, A.Vogel; travel support: Pfizer, Gilead, GSK; advisory boards: Pfizer, MSD, GSK, Sanofi, Moderna, Janssen, Aurovir Grit Barten: public funding for the CAPNETZ study conduct from Deutsches Zentrum für Lungenforschung (DZL) and from Pfizer Deutschland GmbH. Daiana Stolz: Honoraria: AstraZeneca, Berline-Chemie Menarini, Boehringer Ingelheim, Chiesi, CSL Behring, Insmed, GSK. Pfizer, MSD, Novartis, Sanofi, Vifor, Roche, OM-Pharma, Roche. Leadership: Current GOLD representative for Switzerland.
